CN Patent

CN121794380A — 使用prkag2靶向性抗体-寡核苷酸缀合物的组合物和方法

Assigned to Atrem Therapy Company · Expires 2026-04-03 · 0y expired

What this patent protects

本文公开了 PRKAG2 抗体寡核苷酸缀合物（AOC）的多核酸分子、药物组合物和使用方法。

USPTO Abstract

本文公开了 PRKAG2 抗体寡核苷酸缀合物（AOC）的多核酸分子、药物组合物和使用方法。

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: CN121794380A
Jurisdiction: CN
Classification: —
Expires: 2026-04-03
Drug substance claim: No
Drug product claim: No
Assignee: Atrem Therapy Company
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.